# Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

> **NCT04742361** · PHASE3 · COMPLETED · sponsor: **ABX advanced biochemical compounds GmbH** · enrollment: 136 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Recurrent

## Interventions

- **DRUG:** [18F]PSMA-1007

## Key facts

- **NCT ID:** NCT04742361
- **Lead sponsor:** ABX advanced biochemical compounds GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-27
- **Primary completion:** 2023-06-23
- **Final completion:** 2025-05-05
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04742361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04742361, "Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04742361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*